$TVGN News

Last published 3d ago

3d agoTVGN TVGNWTevogen Complements Capital Access with Two-Year Extension to Loan AgreementGlobeNewswireTevogen secures two extra years of capital access, with up to $28.6 million in borrowing capacity through May 2029, complementing its existing ATM program.
3d agoTVGN TVGNWTevogen Complements Capital Access with Two-Year Extension to Loan AgreementGlobeNewswireUp to $28.6 million in borrowing capacity through May 2029 WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), a healthcare company focused on
1mo agoTVGN TVGNWUPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCGlobeNewswireWARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare
1mo agoTVGN TVGNWTevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCGlobeNewswireWARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare
3mo agoTVGN TVGNWTevogen Bio Holdings Inc. Becomes Tevogen Inc.GlobeNewswireWARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it will operate under the name Tevogen Inc., following approval by
4mo agoTVGN TVGNWTevogen Bio Announces 2026 Annual Meeting of StockholdersGlobeNewswireWARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) announced that its 2026 Annual Meeting of Stockholders (the "Annual Meeting)" is
5mo agoTVGN TVGNWTevogen Announces Formation of a Healthcare Services InitiativeGlobeNewswireWilliam Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen
5mo agoTVGN TVGNWTevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueGlobeNewswireWARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its
5mo agoTVGN TVGNWTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services OrganizationGlobeNewswireWARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to
5mo agoTVGN TVGNWLetter to Shareholders from CEO Dr. Ryan SaadiGlobeNewswireWARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on building a
6mo agoTVGN TVGNWTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market CloseGlobeNewswireWARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a securities purchase agreement for a private investment in
6mo agoTVGN TVGNWTevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalGlobeNewswireWARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including
7mo agoTVGN TVGNWTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthGlobeNewswirePotential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries,
7mo agoTVGN TVGNWTevogen Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireWARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the
8mo agoTVGN TVGNWTevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share UtilizationGlobeNewswireLead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until
8mo agoTVGN TVGNWTevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI InfrastructureGlobeNewswireWARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced performance advancements for its artificial intelligence platform, operated through
8mo agoTVGN TVGNWTevogen Names Leadership Team to Execute Diversified Growth StrategyGlobeNewswireWARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the
8mo agoTVGN TVGNWLetter to Shareholders from CEO Dr. Ryan SaadiGlobeNewswireWARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve into a
8mo agoTVGN TVGNWTevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal PharmaceuticalGlobeNewswireWARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI")
8mo agoTVGN TVGNWTevogen Announces Reverse Stock SplitGlobeNewswireWARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors (the "Board") has approved a reverse stock split of its
8mo agoTVGN TVGNWTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research OrganizationGlobeNewswireWARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to
8mo agoTVGN TVGNWUPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform ClinicusGlobeNewswireWARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent
8mo agoTVGN TVGNWTevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform ClinicusGlobeNewswireWARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent
9mo agoTVGN TVGNWTevogen Board to Evaluate Potential One-Time Special Cash Dividend to ShareholdersGlobeNewswireWARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential
9mo agoTVGN TVGNWTevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including RevenueGlobeNewswireWARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that the current time- and individual performance-based long-term stock incentive
10mo agoTVGN TVGNWTevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025GlobeNewswireJan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reported
10mo agoTVGN TVGNWTevogen CEO Donates Shares to Support Education for Underprivileged ChildrenGlobeNewswireWARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000
10mo agoTVGN TVGNWTevogen CEO Donates Personal Shares to Support Local Fire DepartmentGlobeNewswireWARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal
11mo agoTVGN TVGNWTevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common StockGlobeNewswireWARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of
11mo agoTVGN TVGNWTevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in MedicineGlobeNewswireWARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen's Board of Directors and Professor
11mo agoTVGN TVGNWTevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue OutlookGlobeNewswireWARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most
12mo agoTVGN TVGNWTevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-QGlobeNewswireWARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30,
1y agoTVGN TVGNWTevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVIDGlobeNewswireThis milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489
1y agoTVGN TVGNWTevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash BurnGlobeNewswireWARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP
1y agoTVGN TVGNWTevogen Senior Management Engages with Business and Community Leaders and Highlights Recent ProgressGlobeNewswireWARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma
1y agoTVGN TVGNWTevogen Updates on TVGN 489 Following Growing Long COVID Patient InterestGlobeNewswireCompany intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of patient inquiries,
1y agoMSFT TVGN TVGNWTevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data ExpansionGlobeNewswireBeta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their tar
1y agoTVGN TVGNWTevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVIDGlobeNewswireWARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID,
1y agoTVGN TVGNWTevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million AmericansGlobeNewswireWARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary
1y agoTVGN TVGNWTevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in BostonGlobeNewswireWARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will
1y agoTVGN TVGNWTevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B InfectionGlobeNewswireRisk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")
1y agoTVGN TVGNWTevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell PlatformGlobeNewswireWARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for
1y agoTVGN TVGNWTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and LymphomasGlobeNewswireThe risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000
1y agoTVGN TVGNWTevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2GlobeNewswireWARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune
1y agoTVGN TVGNWTevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureGlobeNewswireWARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting
1y agoTVGN TVGNWTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health EquityGlobeNewswireWARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi,
1y agoTVGN TVGNWTevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsGlobeNewswireWARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as
1y agoTVGN TVGNWTevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaGlobeNewswireWARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations
1y agoTVGN TVGNWREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development EffortsGlobeNewswireIncludes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage
1y agoTVGN TVGNWTevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth MomentumGlobeNewswireExpenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to